Literature DB >> 11124821

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

H B El-Serag1, A C Mason, C Key.   

Abstract

The recent increase in the incidence of hepatocellular cancer in the United States is thought to underlie the rising mortality of this malignancy. However, it remains unknown whether survival of patients with hepatocellular carcinoma (HCC) has changed during the same time period. Using the SEER database (Surveillance, Epidemiology, and End Results) of the National Cancer Institute, we examined the temporal changes and determinants of survival among patients with histologically proven HCC over a 20-year period. Between 1977 and 1996, 7,389 patients diagnosed with HCC were followed in the survival database of SEER. The overall 1-year relative survival rate increased from 14% (95% confidence intervals (CI): 12-16) during 1977-1981 to 23% (95% CI: 21-24) during 1992 to 1996. Between the same two time periods, less improvement was seen in the 5-year survival rates, which increased from 2% (95% CI: 1-3) to only 5% (95% CI: 4-7). The median survival increased slightly from 0.57 years during 1977 to 1981 to 0.64 years during 1992 to 1996. In general, there were no significant differences in survival between men and women or between ethnic groups. During 1987 to 1991, a small fraction (0.8%) of patients underwent radical surgery; these patients had 1-year survival of 59% (95% CI: 35-83%), and 5-year survival of 35% (95% CI: 12-58%). Similar rates were seen during 1992-1996. In conclusion, a small improvement in survival of patients with HCC was seen between 1977 and 1996. Most of this apparent benefit is restricted to the first year following cancer diagnosis, raising the possibility of lead-time bias. There were no significant differences related to gender or ethnicity.

Entities:  

Mesh:

Year:  2001        PMID: 11124821     DOI: 10.1053/jhep.2001.21041

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 2.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

3.  Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.

Authors:  Sean F Altekruse; Katherine A McGlynn; Lois A Dickie; David E Kleiner
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

4.  Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study.

Authors:  Hla-Hla Thein; Edwin Khoo; Michael A Campitelli; Ahmad Zaheen; Qilong Yi; Prithwish De; C C Earle
Journal:  CMAJ Open       Date:  2015-04-02

5.  Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival.

Authors:  Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

6.  Effects and mechanisms of silibinin on human hepatoma cell lines.

Authors:  John-J Lah; Wei Cui; Ke-Qin Hu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

7.  Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study.

Authors:  E Berber; S Rogers; A Siperstein
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

Review 8.  Screening for hepatocellular carcinoma: why, when, how?

Authors:  Miguel R Arguedas
Journal:  Curr Gastroenterol Rep       Date:  2003-02

9.  Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.

Authors:  Gopalakrishnan Ramakrishnan; Sundaram Jagan; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Invest New Drugs       Date:  2008-07-30       Impact factor: 3.850

10.  Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations.

Authors:  Yashu Liu; Jintang He; Chen Li; Ricardo Benitez; Sherry Fu; Jorge Marrero; David M Lubman
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.